Cargando…

Severe toxicity caused by sorafenib in hepatocellular carcinoma match the data from renal cell carcinoma

Detalles Bibliográficos
Autores principales:	Lamarca, A, Feliu, J, Barriuso, J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3304405/ https://www.ncbi.nlm.nih.gov/pubmed/22294185 http://dx.doi.org/10.1038/bjc.2012.25

Ejemplares similares

Comment on “Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma”
por: Qian, Xinye
Publicado: (2023)

Response to: “Comment on Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma”
por: Famularo, Simone, et al.
Publicado: (2023)

Long-Term Regression after Discontinuation of Regorafenib Administered for Sorafenib-Refractory Hepatocellular Carcinoma
por: Bae, Heewon, et al.
Publicado: (2023)

PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma
por: Yang, Xiao-Dong, et al.
Publicado: (2021)

Sorafenib with or without concurrent transarterial chemoembolization in hepatocellular carcinoma: a cautionary comment of STAH trial
por: Chen, Jia-Hao, et al.
Publicado: (2020)

Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs
por: Marconato, Laura, et al.
Publicado: (2020)

Reply: Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
por: Feliu, J, et al.
Publicado: (2011)

Atezolizumab plus bevacizumab versus sorafenib as first‐line treatment for unresectable hepatocellular carcinoma: a cost‐effectiveness analysis
por: Hou, Yanli, et al.
Publicado: (2020)

Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study
por: Cai, Wen, et al.
Publicado: (2019)

Toxic Epidermal Necrolysis Associated with Sorafenib and Tosufloxacin in a Patient with Hepatocellular Carcinoma
por: Choi, Mun Ki, et al.
Publicado: (2011)

Impact of lenvatinib on renal function compared to sorafenib for unresectable hepatocellular carcinoma
por: Sasaki, Ryu, et al.
Publicado: (2022)

Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib
por: Di Fiore, F, et al.
Publicado: (2011)

Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
por: Mousa, Ali Ben
Publicado: (2008)

Sorafenib for the treatment of unresectable hepatocellular carcinoma
por: Furuse, Junji
Publicado: (2008)

Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
por: Sanoff, Hanna K., et al.
Publicado: (2016)

Octreotide and hepatocellular carcinoma
por: Farinati, F, et al.
Publicado: (2007)

Revision and addendum to the manuscript titled “Propensity score matching study of 325 patients with spontaneous rupture of hepatocellular carcinoma”
por: Wang, Wei, et al.
Publicado: (2023)

Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular Carcinoma
por: Mir, Olivier, et al.
Publicado: (2012)

Renal cell carcinoma and the use of sorafenib
por: Larkin, James MG, et al.
Publicado: (2006)

Sorafenib Monotherapy Versus Sorafenib Combined with Regional Therapies for Hepatocellular Carcinoma Patients with Pulmonary Oligometastases: A Propensity Score-matched Analysis
por: Chen, Jinbin, et al.
Publicado: (2018)

An unusual cause of right ventricular wall rupture during radiofrequency ablation of hepatocellular carcinoma
por: Sethi, Sameer, et al.
Publicado: (2018)

Cerebrovascular Accidents Associated with Sorafenib in Hepatocellular Carcinoma
por: Saif, Muhammad W., et al.
Publicado: (2011)

Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma
por: Almhanna, Khaldoun, et al.
Publicado: (2009)

Evolving role of Sorafenib in the management of hepatocellular carcinoma
por: Ziogas, Ioannis A, et al.
Publicado: (2017)

Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
por: Ko, Yi-Ling, et al.
Publicado: (2020)

Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma
por: Ikeda, Atsuyuki, et al.
Publicado: (2021)

Transarterial chemoembolization with or without sorafenib for hepatocellular carcinoma: A real-world propensity score-matched study
por: Peng, Tzu-Rong, et al.
Publicado: (2021)

Megestrol treatment in patients with hepatocellular carcinoma
por: Farinati, F, et al.
Publicado: (2001)

Drug-eluting beads in hepatocellular carcinoma
por: Abe, Hiroyuki, et al.
Publicado: (2017)

Hepatocellular carcinoma biomarkers, an imminent need
por: Zamora-León, S Pilar
Publicado: (2021)

Implications of pseudogenes for the prognosis of hepatocellular carcinoma
por: Liu, Zaoqu, et al.
Publicado: (2023)

Toxic thyroid carcinoma: A new case
por: Nair, C. Gopalakrishnan, et al.
Publicado: (2012)

Honey and renal cell carcinoma
por: Wiwanitkit, Viroj
Publicado: (2011)

Sorafenib in the management of metastatic renal cell carcinoma
por: Guevremont, C., et al.
Publicado: (2009)

Reply: Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer
por: van der Veldt, A A M, et al.
Publicado: (2009)

Acalculous Cholecystitis in a Patient with Hepatocellular Carcinoma on Sorafenib
por: Sanda, Mariko, et al.
Publicado: (2011)

Liver Resection after Downstaging Hepatocellular Carcinoma with Sorafenib
por: Barbier, L., et al.
Publicado: (2011)

Sorafenib Combined with Cryoablation to Treat Unresectable Hepatocellular Carcinoma
por: Ni, Hong, et al.
Publicado: (2011)

Transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma
por: SHAO, WENBO, et al.
Publicado: (2014)

Critical appraisal of the role of sorafenib in the management of hepatocellular carcinoma
por: Pan, Jen-Jung, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_healdt6ikqa34kakj439sgc9l5